| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA3366750 | B | Inhibition of HIV1 gp41-induced cell-cell fusion between viral envelope expressing human HL2/3 cells to CD4/CCR5 receptor expressing TZM-bl cells after 6 to 8 hrs by luciferase assay | Human immunodeficiency virus 1 | 21 | ALA3351900 | cell-based format | Scientific Literature | |
| 2. | ALA3366751 | F | Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of viral p24 antigen production by ELISA | Human immunodeficiency virus 1 | 15 | ALA3351900 | organism-based format | Scientific Literature | |
| 3. | ALA3366752 | A | Cytotoxicity against human MT2 cells after 4 days by XTT assay | Homo sapiens | 15 | ALA3351900 | cell-based format | Scientific Literature | |
| 4. | ALA3366753 | F | Antiviral activity against HIV1 BaL infected in human MT2 cells assessed as inhibition of viral replication | Human immunodeficiency virus 1 | 15 | ALA3351900 | organism-based format | Scientific Literature | |
| 5. | ALA3366754 | T | Selectivity index, ratio of CC50 for human MT2 cells to EC50 for HIV1 3B infected in human MT2 cells | 15 | ALA3351900 | cell-based format | Scientific Literature | ||
| 6. | ALA3366755 | B | Inhibition of HIV1 gp41-induced cell-cell fusion between viral envelope expressing human HL2/3 cells to CD4/CCR5 receptor expressing TZM-bl cells compound preincubated for 1 hr measured after 48 hrs by prime/wash assay | Human immunodeficiency virus 1 | 4 | ALA3351900 | cell-based format | Scientific Literature | |
| 7. | ALA3366756 | B | Inhibition of HIV1 gp41-induced cell-cell fusion between viral envelope expressing human HL2/3 cells to CD4/CCR5 receptor expressing TZM-bl cells compound preincubated for 1 hr followed by wash out measured after 48 hrs by prime/wash assay | Human immunodeficiency virus 1 | 4 | ALA3351900 | cell-based format | Scientific Literature | |
| 8. | ALA3366757 | B | Ratio of EC50 for HIV1 gp41-induced cell-cell fusion between viral envelope expressing human HL2/3 cells to CD4/CCR5 receptor expressing TZM-bl cells with wash out to EC50 for HIV1 gp41-induced cell-cell fusion between viral envelope expressing human HL2/3 cells to CD4/CCR5 receptor expressing TZM-bl cells | Human immunodeficiency virus 1 | 4 | ALA3351900 | cell-based format | Scientific Literature | |
| 9. | ALA3366758 | B | Inhibition of HIV1 gp41 NHR assessed as inhibition of 6HB formation by FRET assay | Human immunodeficiency virus 1 | 8 | ALA3351900 | single protein format | Scientific Literature | |
| 10. | ALA3366759 | B | Inhibition of HIV1 gp41 NHR assessed as inhibition of 6HB formation after 30 mins by size-exclusion HPLC analysis | Human immunodeficiency virus 1 | 2 | ALA3351900 | single protein format | Scientific Literature | |
| 11. | ALA3366760 | F | Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of viral entry compound treated at 100 uM at 1 hr post infection measured 3 to 4 days post infection by time-of-addition assay | Human immunodeficiency virus 1 | 1 | ALA3351900 | organism-based format | Scientific Literature | |
| 12. | ALA3361441 | F | Antiviral activity against T20-sensitive HIV1 NL4-3 harboring gp41 D36G mutant infected in human MT2 cells | Human immunodeficiency virus 1 | 2 | ALA3351900 | organism-based format | Scientific Literature | |
| 13. | ALA3361442 | F | Antiviral activity against T20-resistant HIV1 NL4-3 harboring gp41 D36G/V38A mutant infected in human MT2 cells | Human immunodeficiency virus 1 | 2 | ALA3351900 | organism-based format | Scientific Literature | |
| 14. | ALA3361443 | F | Antiviral activity against T20-resistant HIV1 NL4-3 harboring gp41 D36G/V38A/N42D mutant infected in human MT2 cells | Human immunodeficiency virus 1 | 2 | ALA3351900 | organism-based format | Scientific Literature | |
| 15. | ALA3361444 | F | Antiviral activity against T20-resistant HIV1 NL4-3 harboring gp41 D36G/N42T/N43K mutant infected in human MT2 cells | Human immunodeficiency virus 1 | 2 | ALA3351900 | organism-based format | Scientific Literature | |
| 16. | ALA3361445 | F | Antiviral activity against T20-resistant HIV1 NL4-3 harboring gp41 D36G/V38E/N42S mutant infected in human MT2 cells | Human immunodeficiency virus 1 | 2 | ALA3351900 | organism-based format | Scientific Literature | |
| 17. | ALA3361446 | F | Antiviral activity against T20-resistant HIV1 NL4-3 harboring gp41 D36G/V38A/N42T mutant infected in human MT2 cells | Human immunodeficiency virus 1 | 2 | ALA3351900 | organism-based format | Scientific Literature | |
| 18. | ALA3361447 | F | Ratio of EC50 for T20-resistant HIV1 NL4-3 harboring gp41 D36G/V38A mutant infected in human MT2 cells to EC50 for T20-sensitive HIV1 NL4-3 harboring gp41 D36G mutant infected in human MT2 cells | Human immunodeficiency virus 1 | 2 | ALA3351900 | organism-based format | Scientific Literature | |
| 19. | ALA3361448 | F | Ratio of EC50 for T20-resistant HIV1 NL4-3 harboring gp41 D36G/V38A/N42D mutant infected in human MT2 cells to EC50 for T20-sensitive HIV1 NL4-3 harboring gp41 D36G mutant infected in human MT2 cells | Human immunodeficiency virus 1 | 2 | ALA3351900 | organism-based format | Scientific Literature | |
| 20. | ALA3361449 | F | Ratio of EC50 for T20-resistant HIV1 NL4-3 harboring gp41 D36G/N42T/N43K mutant infected in human MT2 cells to EC50 for T20-sensitive HIV1 NL4-3 harboring gp41 D36G mutant infected in human MT2 cells | Human immunodeficiency virus 1 | 2 | ALA3351900 | organism-based format | Scientific Literature |
The page will load shortly, Thanks for your patience!